Adiponectin/leptin ratio predicts the remission of metabolic syndrome: A pilot study

Int J Cardiol. 2024 Apr 1:400:131791. doi: 10.1016/j.ijcard.2024.131791. Epub 2024 Jan 18.

Abstract

Background: Adipokines are key mediators of inflammation in metabolic syndrome perpetuating the effect of excess nutrient intake by setting a self-maintaining vicious circle. Here, we assess levels of adiponectin and leptin in a cohort of individuals with MetS undergoing dietary and behavioral counselling. Specifically, we investigate their role as predictors of metabolic syndrome remission after 1 year.

Methods: Patients with MetS (n = 127) received behavioral and dietary recommendations and were followed-up for 1 year. Serum was available for 108 individuals, levels of adiponectin and leptin were tested at baseline, at 6 months (t1) and after 1 year (t2). Adiponectin/leptin (A/L) ratio was also calculated and tested for predictive ability.

Result: At the end of the follow-up period, 59 patients did not show enough criteria to define MetS anymore. When considered alone, adiponectin and leptin levels did not show difference over follow-up. Their ratio instead was significantly reduced at t1 and t2 with respect to baseline. Remitters also showed lowers level of leptin and A/L ratio as compared to non-remitters at t1. At this timepoint, A/L ratio independently predicted MetS remission at 1 year [OR 9.082 95%CI (1.394-59.160), p = 0.021]. Bootstrap resampling analysis internally validated our findings.

Conclusions: Preliminary results from our pilot study suggest that MetS remission after counselling associates with changes in adipokine balance. A/L ratio decreases overtime and its value at 6 months can independently predict MetS remission.

Keywords: Adipocytokine; Adiponectin; Adiponectin/leptin ratio; Inflammation; Leptin; Metabolic syndrome.

MeSH terms

  • Adipokines
  • Adiponectin
  • Humans
  • Leptin*
  • Metabolic Syndrome* / diagnosis
  • Pilot Projects

Substances

  • Leptin
  • Adiponectin
  • Adipokines